|
Glioma
|
0.200 |
Biomarker
|
disease |
BEFREE |
MiR-20a mediated TMZ-resistance in glioblastoma cells through negatively regulating LRIG1 expression, which suggesting that miR-20a and LRIG1 would be potential therapeutic targets for glioma therapy.
|
25960225 |
2015 |
|
Glioma
|
0.200 |
Biomarker
|
disease |
BEFREE |
These findings indicate that LRIG2 possesses distinct functions compared with LRIG1 and validate the attractiveness of LRIG2 as a target in glioma therapy.
|
19421009 |
2009 |
|
Glioma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
LRIG1-3 mRNA was detected in all human glioma cell lines and matched glioma samples, with large differences in the expression levels.
|
16532360 |
2006 |
|
Glioma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Thus, for the first time, changes in physiological Lrig1 expression have been linked to gliomagenesis, whereby the SNP rs11706832 may affect glioma risk by regulating LRIG1 expression.
|
29391393 |
2018 |
|
Glioma
|
0.200 |
Biomarker
|
disease |
BEFREE |
The soluble LRIG1 ectodomain is demonstrated to be shed naturally and inhibit the progression of glioma.
|
25353163 |
2014 |
|
Glioma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
We constructed an enhanced green fluorescent protein plasmid (pEGFP) system, pEGFP-C1-LRIG1, for overexpression of LRIG1, and transfected it into human glioma cell line SHG-44.
|
25860915 |
2015 |
|
Glioma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Resveratrol can inhibit the growth and proliferation of glioma and promote its apoptosis through upregulating the LRIG1 gene expression, which plays the effect of antiglioma growth, revealing that LRIG1 is a new biological target of resveratrol in antiglioma cell proliferation and growth.
|
29745084 |
2019 |
|
Glioma
|
0.200 |
Biomarker
|
disease |
BEFREE |
LRIG1 functions as a tumor suppressor in the pathogenesis of glioma via EGFR/Akt/c-Myc activation.
|
23124613 |
2013 |
|
Glioma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
LRIG1 was negatively correlated with BCL-2 expression in glioma tissue and U251/MDR cells, and upregulation of LRIG1 can enhance chemosensitivity and inhibit BCL-2 expression.
|
25048475 |
2014 |
|
Glioma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that LRIG1 restricted glioma aggressiveness by inhibiting cell proliferation, migration and invasion.
|
23337938 |
2013 |
|
Glioma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
In addition, we showed that the expression level of LRIG1 was significantly negatively correlated with BCL-2 and MnSOD expression in glioma.
|
25449296 |
2015 |
|
Glioma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
These findings suggest that upregulation of LRIG1 expression enhances the CDDP sensitivity in the glioma cell line U251.
|
23581227 |
2012 |
|
Colorectal Carcinoma
|
0.140 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, there was a great heterogeneity in the expression of the LRIG1 protein in colorectal cancer, which was not related to gene dosage of the LRIG1 gene.
|
17851870 |
2007 |
|
Colorectal Carcinoma
|
0.140 |
AlteredExpression
|
disease |
BEFREE |
LRIG1 is down-regulated in various epithelial cancers, including bladder, breast, and colorectal cancer, suggesting that it functions as a tumor suppressor.
|
30248341 |
2018 |
|
Colorectal Carcinoma
|
0.140 |
AlteredExpression
|
disease |
BEFREE |
Finally, in a cohort of xenopatients, stratified for response to cetuximab, we observed an inverse association between the expression level of LRIG1 and CRC progression upon CTX treatment.
|
31052457 |
2019 |
|
Colorectal Carcinoma
|
0.140 |
PosttranslationalModification
|
disease |
BEFREE |
A significant increase in LRIG1 methylation was identified in CRC specimens compared to adjacent normal tissues and that it was negatively correlated with its mRNA and protein expression.
|
26159916 |
2015 |
|
Malignant tumor of colon
|
0.110 |
Biomarker
|
disease |
BEFREE |
In fact, G2.2 robustly inhibited CSCs' abundance (measured by levels of CSC markers, e.g., CD133, DCMLK1, LGR5, and LRIG1) and self-renewal (quaternary spheroids) in colon cancer xenografts.
|
30337351 |
2019 |
|
Colorectal Neoplasms
|
0.110 |
AlteredExpression
|
group |
BEFREE |
Lrig1 is expressed at low levels in several cancer types but is overexpressed in some prostate and colorectal tumors.
|
21821674 |
2011 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
LRIG1 is frequently down-regulated in human cancer, and high levels of LRIG1 in tumor tissue are associated with favorable clinical outcomes in several tumor types including non-small cell lung cancer (NSCLC).
|
30429017 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNFα expression and receptor tyrosine kinase signaling.
|
22241084 |
2012 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
LRIG1 expression has prognostic significance in various human cancers.In this study, we first used the quantitative polymerase chain reaction (qPCR) and immunohistochemical analysis of 36 and 182 NSCLC patient tissues to analyze the LRIG1 expression respectively.
|
26632716 |
2015 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Lrig1 is expressed at low levels in several cancer types but is overexpressed in some prostate and colorectal tumors.
|
21821674 |
2011 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
<i>In silico</i> analyses of The Cancer Genome Atlas data sets revealed consistent correlations between the expression of the transcripts encoding LRIG1 and its interactors ZBTB16 and PTPRK and inverse correlations between the transcripts encoding LRIG1 and GLRX3.
|
29317492 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
LRIG1 and Fascin-1 were differently expressed in cancer and normal lung tissue in patients with NSCLC, which could be a biomarker for mediastinal lymph node metastasis in NSCLC patients.
|
28230028 |
2016 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High LRIG1 expression was associated with a good prognosis in malignant tumors (HR: 0.49, 95% CI=0.39-0.59).
|
30123358 |
2018 |